Terms ending in 2037
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,136,310 | Iminotetrahydropyrimidinone Derivatives as Plasmepsin V Inhibitors In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 10,654,861 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 10,766,906 | Fused Hexacyclic Imidazole Derivatives as Modulators of TNF Activity In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 11,912,721 | Fused Pentacyclic Imidazole Derivatives In force · High confidence | Sanofi and Ucb Biopharma SPRL | In force | High confidence | |
| US 11,345,662 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 11,820,746 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 12,071,404 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides In force · High confidence | Ucb Pharma GmbH | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.